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Summary
Background Data describing the coagulopathy of Crimean–Congo haemorrhagic fever are scarce. We did rotational 
thromboelastometry (ROTEM) and conventional coagulation testing in patients with Crimean–Congo haemorrhagic 
fever to increase our understanding of the coagulopathy of this infectious disease.
Methods We did a prospective observational cohort study of adults aged 18 years and older and admitted to hospitals 
with PCR-confirmed Crimean–Congo haemorrhagic fever in Samsun and Tokat, Turkey. Demographic, clinical, and 
laboratory data were collected and blood samples for ROTEM analysis and coagulation testing were drawn at admission 
and during hospital admission and convalescence (up to 30 days after onset of illness). For the ROTEM analysis we 
recorded the following extrinsically activated ROTEM (EXTEM S) variables, with normal ranges indicated: clotting time 
(38–79 s), clot formation time (34–159 s), amplitude at 10 min after clotting time (43–65 mm), maximum clot firmness 
(50–72 mm), and maximum lysis (>15% at 1 h). The following fibrin-specific ROTEM (FIBTEM S) variables were also 
recorded: amplitude at 10 min after clotting time (normal range 7–23 mm) and maximum clot firmness (9–25 mm). 
Disease severity was assessed by Swanepoel criteria, severity grading score (SGS), and the severity scoring index (SSI), 
with mild disease defined as meeting no Swanepoel criteria, graded mild by SSI, and graded low risk by SGS. 
Findings Between May 27, 2015, and Aug 2, 2015, 65 patients with confirmed Crimean–Congo haemorrhagic fever 
were recruited and had blood taken at 110 time points. Most were male (40 [62%] of 65) with mild disease (49 [75%] 
of 65). Haemorrhage occurred in 13 (20%; 95% CI 11·1–31·8) of 65 patients and 23 (35%) of 65 received blood 
products (15 received fresh frozen plasma and eight received red blood cell concentrates), and 21 patients received 
platelet transfusions. At admission, the following EXTEM S variables differed significantly between mild cases and 
moderate to severe cases: median clotting time 56 s (range 42–81; IQR 48–64) versus 69 s (range 48–164; IQR 54–75; 
p=0·01); mean amplitude at 10 min after clotting time 45·1 mm (SD 7·0) versus 33·9 mm (SD 8·6; p<0·0001); 
median clot formation time 147 s (range 72–255; IQR 101–171) versus 197 s (range 98–418; IQR 156–296; p=0·006); 
and maximum clot firmness 54·4 mm (SD 7·2) versus 45·1 mm (SD 12·5; p=0·003). The EXTEM S variables were 
compared at different time points; maximum clot firmness (p=0·024) and amplitude at 10 min after clotting time 
(p=0·090) were lowest on days 4–6 of illness. We found no significant differences in FIBTEM variables between mild 
and moderate to severe cases (median amplitude at 10 min, 13 mm [range 8–20; IQR 11–15] vs 12 mm [range 6–25; 
IQR 10–15; p=0·68]; and median maximum clot firmness, 15 mm [range 9–60; IQR 13–21] vs 17 mm [range 7–39; 
IQR 13–23; p=0·21]); and no hyperfibrinolysis (maximum lysis >15%).
Interpretation Coagulopathy of Crimean–Congo haemorrhagic fever is related to defects in clot development and 
stabilisation that are more marked in severe disease than in mild disease. The combination of normal and slightly 
deranged coagulation screens and FIBTEM results with the absence of hyperfibrinolysis suggests that the coagulopathy 
of Crimean–Congo haemorrhagic fever relates to platelet dysfunction.
Funding Wellcome Trust, UK Ministry of Defence, and National Institute for Health Research Health Protection 
Research Unit.
Copyright © 2019. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Crimean–Congo haemorrhagic fever is a potentially fatal 
acute viral disease that is widespread across southern 
Africa and eastern Europe, Russia, and the Middle East,1 
and is seen occasionally in travellers returning from 
endemic areas.2 Crimean–Congo haemorrhagic fever 
virus is transmitted to humans through tick bites or 
direct exposure to blood and tissues of infected animals 
and humans. The disease has been associated with 
case fatality rates of 10–40%3 and has been designated a 
priority pathogen for research and development by 
WHO.4
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The evolution and pathogenesis of the coagulopathy 
of viral haemorrhagic fevers are poorly understood, 
particularly for Crimean–Congo haemorrhagic fever. 
Concentrations of protein S and protein C, activated 
protein C resistance, and D-dimer were not associated 
with mortality in one study of 83 patients with Crimean–
Congo haemorrhagic fever.5 Thrombocytopenia and 
platelet dysfunction have been shown to occur in Lassa 
fever6–8 and in Ebola virus disease.9
Traditional screening coagulation tests such as 
activated partial thromboplastin time provide information 
about coagulation factor deficiencies, but not the 
full haemostatic capacity of clot formation, thrombin 
generation, platelet number and function, or fibrinolytic 
activation. These tests also have a laboratory turnaround 
time that can delay delivery of therapeutic interventions. 
Rotational thromboelastometry (ROTEM) is a test with a 
quick turnaround time that can be done near the patient 
(ie, outside of laboratories) and can give a more 
comprehensive overview of haemostatic status. The test 
is derived from a technique that was first developed 
in 1948,10 and analyses three phases of coagulation 
(initiation, amplification, and propagation), reflecting the 
interactions of the cellular and plasma components of 
coagulation and the activity of the fibrinolytic system.11 A 
whole blood sample is placed in a cuvette and a cylindrical 
pin immersed, maintaining a gap bridged by the 
blood. The pin is rotated and, as the blood begins to clot, 
its movement is restricted and the changes in 
mechanical kinetics that result can be plotted to generate 
typical curves (known as TEMograms) and numerical 
measurements (figure 1).
ROTEM values have been used to detect and manage 
coagulopathy in haemorrhagic disorders, including 
traumatic coagulopathy, post-partum haemorrhage, 
intensive care, and surgery (eg, liver transplantation). 
ROTEM analysis of a cohort of 53 patients with dengue 
showed substantial impairment in thromboelastometry 
values.12 A similar technique, thromboelastography, was 
done on two patients with Ebola virus disease in the 
UK,13 showing evidence of a coagulopathy, followed by 
hypercoagulability on recovery.
We did ROTEM analysis alongside conventional coa- 
gulation testing to improve understanding of the 
coagulopathy of Crimean–Congo haemorrhagic fever, in 
the hope that these new insights would inform new 
approaches to improving clinical outcomes.
Methods
Study design
For this prospective observational cohort study, we 
collected demographic, clinical, and laboratory data from 
patients aged 18 years and older who were consecutively 
admitted to hospital with Crimean–Congo haemorrhagic 
fever in Samsun, Turkey (Ondokus Mayis University 
Hospital), and Tokat, Turkey (Tokat State Hospital 
and Gaziosmanpasa University Hospital), between 
May 27, 2015, and Aug 2, 2015. 
The Ministry of Defence Research and Ethics 
Committee (UK: 571/MODREC/14) and Ondokus Mayis 
Research in context
Evidence before this study
We searched Medline and PubMed for studies published between 
May 1, 1976, and July 1, 2018, reporting clotting abnormalities 
in humans. We used the following keywords: “CCHF”, 
“Crimean-Congo Hemorrhagic Fever”, “Ebola”, “ yellow fever”, 
“viral haemorrhagic fever”, “dengue”, “thromboelastography”, 
and “thromboelastometry”, and found three peer-reviewed 
studies: one reporting the use of thromboelastography data for 
two cases of Ebola virus disease; and two cross-sectional studies 
of rotational thromboelastometry (ROTEM) in dengue virus 
infection. Before our study, Crimean–Congo haemorrhagic fever 
was known to be associated with substantial haemorrhage, and 
haemorrhagic manifestations and abnormal haematological 
variables have been shown to be associated with a poor clinical 
outcome. The evolution and pathogenesis of the coagulopathy 
of viral haemorrhagic fevers are poorly understood and there are 
few data about the coagulopathy of Crimean–Congo 
haemorrhagic fever.
Added value of this study
This study is, to the best of our knowledge, the first use of a 
global haemostasis test in Crimean–Congo haemorrhagic fever 
and the largest and most complete evaluation of ROTEM in any 
viral haemorrhagic fever. We show that reversible coagulopathy 
in Crimean–Congo haemorrhagic fever is common, 
haemorrhage frequently occurs in severe disease, and that 
traditional laboratory tests (prothrombin time and activated 
partial thromboplastin time) do not show substantial changes 
in individuals with Crimean–Congo haemorrhagic fever. 
These findings suggest that these tests are not detecting the 
cause of the coagulopathy and that bleeding is likely to be due 
to a defect in platelets or fibrinolysis. ROTEM shows no 
evidence that hyperfibrinolysis accounts for bleeding and 
excludes disseminated intravascular coagulation as the 
predominant cause of the bleeding. The defect appears to lie in 
the contribution of platelets to clot firmness. This study 
provides, to our knowledge, the first evidence that the 
coagulopathy in Crimean–Congo haemorrhagic fever 
relates to platelet dysfunction.
Implications of all available evidence
With no proven therapeutics available to treat Crimean–Congo 
haemorrhagic fever, management of coagulopathy and the 
associated haemorrhage is a key facet of supportive care. 
Global haemostasis tests such as ROTEM might improve early 
detection and rationalised transfusion. Future studies should 
investigate the platelet defect in more detail and investigate the 
implementation of ROTEM-guided blood product replacement.
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University Research and Ethics Committee (Turkey: 
OMU KAEK 2014/739) approved the research and all 
patients provided written informed consent.
Procedures
Diagnosis of Crimean–Congo haemorrhagic fever was 
confirmed on admission by a positive Crimean–Congo 
haemorrhagic fever PCR result (Altona RealStar CCHFV 
1.0, Hamburg, Germany) on blood samples at the 
Ministry of Health reference laboratory in Samsun, 
Turkey. Analysis of Crimean–Congo haemorrhagic fever 
IgM and IgG ELISA (Vectorbest, Novosibirsk, Russia) 
was done on serum at Public Health England, Porton, 
UK. Clinical features, vital signs, and laboratory test 
results were recorded daily on a standardised proforma 
with onset of disease or symptoms recorded as day 0. 
Blood samples for ROTEM analysis were drawn 
during hospital admission and during convalescence 
(days 14–30).
Routine haematological variables (haemoglobin, white 
blood cell count, platelet count, prothrombin time, and 
activated partial thromboplastin time) were analysed by 
use of automated analysers in local ISO/IEC 17025 and 
ISO 15189 standard accredited laboratories (Mindray, 
Shenzhen, China; BC-68700, Shenzhen, China; and 
Succeeder SF-8100, Beijing, China). The laboratory 
(manufacturer’s) normal range for prothrombin time 
was 11–15 s and that for activated partial thromboplastin 
time was 27–45 s. Standard ROTEM analysis was done 
on 3·2% citrated whole blood by use of a ROTEM delta 
point-of-care analyser (Tem International, Munich, 
Germany) according to the manufacturer’s instructions, 
less than 2 h after blood draw. Single-use extrinsically 
activated ROTEM (EXTEM S) and fibrin-specific ROTEM 
(FIBTEM S) assay reagents were used with an automated 
pipette for standardised volumes. Analysis was done 
inside a class 2a biological safety cabinet, with the 
operator wearing personal protective equipment.
We used EXTEM S screening, which gives information 
about clot formation, particularly through the extrinsic 
pathway, and FIBTEM S, which isolates coagulation 
and provides information about the contribution of 
fibrinogen to clot firmness. The following EXTEM 
S variables were recorded: clotting time (time from start 
of the measurement until initiation of clotting; 
manufacturer normal range 38–79 s), clot formation time 
(time from initiation of clotting until a clot firmness of 
20 mm is detected; 34–159 s), amplitude at 10 min after 
clotting time (also known as clot firmness 10 min after 
clot initiation; 43–65 mm), maximum clot firmness 
(clot firmness and overall clot stability; 50–72 mm), 
and maximum lysis (>15% at 1 h). The following 
FIBTEM S variables were recorded: amplitude at 10 min 
after clotting time (manufacturer normal range 
7–23 mm); and maximum clot firmness (9–25 mm). 
PLTEM was calculated by subtracting maximum clot 
firmness for FIBTEM from maximum clot firmness for 
EXTEM, as PLTEM might correlate better with platelet 
count and function than EXTEM.14
Severity of Crimean–Congo haemorrhagic fever was 
assessed in all patients by use of Swanepoel criteria,15 the 
severity grading score (SGS),16 and severity scoring index 
(SSI),17 for the first 5 days of illness (appendix). Patients 
presenting more than 5 days after onset of illness were 
given an SSI score at admission. They were categorised as 
mild if they met none of the Swanepoel criteria and were 
graded as mild by SSI and low risk by SGS. The moderate-
to-severe group comprised all patients graded as moderate 
Figure 1: Rotational thromboelastometry (ROTEM) variables and scaling
Used with permission from Instrumentation Laboratory (Bedford, MA, USA).
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or severe on the SSI, intermediate or high risk on the SGS, 
or with any of the Swanepoel criteria (appendix). Missing 
laboratory variables were scored as zero, but severity 
groups and results were confirmed by singular imputation 
of maximal scores for patients with missing data. 
Patients were given blood products according to clinician 
assessment and blood product use was recorded daily.
Statistical analysis
Descriptive results are reported as frequencies 
(proportions) for categorical variables and means (SD or 
95% CI) or medians (ranges; IQR) for continuous 
variables. Categorical variables were compared between 
subgroups with the Fisher exact test. Continuous 
variables measured at admission were compared by use 
of Student’s t-tests or the Mann-Whitney U-test or 
Kruskal-Wallis test as appropriate. Continuous variables 
measured longitudinally were compared by use of linear 
regression models with robust standard errors and 
adjustment for clustering of measures within patients. 
No imputation for missing data was made because of 
small sample sizes. Hypothesis tests were two-tailed 
(p<0·05) and analyses were done with SPSS, version 24, 
and Stata, version 14.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Between May 27, 2015, and Aug 2, 2015, 65 patients with 
confirmed Crimean–Congo haemorrhagic fever were 
recruited, with 49 (75%) graded as mild severity and two 
(3·1%, 95% CI 0·4–10·7) of 65 patients dying. Imputation 
of missing data at maximal scores changed the severity 
grading in one patient, with no significant changes 
to the results. In addition to positive PCR results, 
Crimean–Congo haemorrhagic fever IgM and IgG ELISA 
was positive in 64 (98%) of 65 patients (negative IgM and 
IgG in one patient who died). Demographic information 
is provided in table 1. 212 ROTEM analyses (EXTEM S, 
n=107; FIBTEM S, n=105) were done on 110 blood 
samples grouped by day of illness: days 0–3 (n=27), 
days 4–6 (n=46), days 7–10 (n=25), and convalescence 
(n=12, median 21 days [IQR 17–30] after onset of illness). 
In 45 (69%) of 65 patients, baseline ROTEM analysis was 
done within 48 h of admission (31 [69%] of these 
45 patients were graded as having mild disease). Of the 
remaining 20 (31%) patients, 14 (70%) had ROTEM 
analysis after 48 h during acute admission and six only 
had ROTEM analysis at follow-up during convalescence.
Haemorrhage occurred in 13 (20%, 95% CI 11·1–31·8) 
of 65 patients, who had a total of 25 days of haemorrhage 
during 424 days of study observation. The sites of 
bleeding were oral (in seven patients), nasal (in seven), 
sputum (in three), vomit (in two), stool (in two), 
intravenous puncture sites (in two), vaginal (in one), 
urine (in one), and skin (in one). 35 (54%) of 65 patients 
developed platelet counts lower than 50 × 10⁹ cells per L 
during admission, with 11 (17%) of 65 having a platelet 
count lower than 20 × 10⁹ cells per L.
Fresh frozen plasma was administered to 15 (23%) of 
65 patients, red blood cell concentrates to eight (12%), 
and platelet transfusion to 21 (32%). 11 (85%) of 
13 patients who developed haemorrhage had received 
blood component therapy before the onset of bleeding. 
At the time of bleeding (25 patient-admission days—ie, total 
days of bleeding during admission for the cohort), 
median platelet count was 44 × 10⁹ cells per L (range 
4 × 10⁹ to 152 × 10⁹; IQR 17 × 10⁹ to 53 × 10⁹), median 
prothrombin time (only available for 24 of the 25 patient-
admission days) was 13 s (range 11–38, IQR 11–14; 
within normal limits for 23 of 24 patients), and median 
activated partial thromboplastin time (only available for 
24 of the 25 patient-admission days) was 48 s 
(range 22–85, IQR 36–56, within normal limits for ten 
All cases 
(n=65)
Mild cases 
(n=49)
Moderate to 
severe cases 
(n=16)
p value
Sex
Male 40 (62%) 31 (63%) 9 (56%) ··
Female 25 (38%) 18 (37%) 7 (44%) 0·77
Mean age, years 53 (15·6) 53·9 (16·6) 50·3 (11·8) 0·43
Tick bite
Yes 45 (69%) 36 (73%) 9 (56%) ··
No 20 (31%) 13 (27%) 7 (44%) 0·22
Mode of admission
Direct 56 (86%) 44 (90%) 12 (75%) ··
Hospital transfer 9 (14%) 5 (10%) 4 (25%) 0·21
Median time from symptom 
onset to admission, days
2 (0–7; 2–4) 3 (1–8; 2–4) 4 (1–8; 3–6) 0·07
Median length of admission, 
days
8 (2–16; 6–10) 8 (3–16; 7–10) 8 (2–11; 6–9) 0·45
Fatal outcome
Yes 2 (3%) 0 (0%) 2 (12%) ··
No 63 (97%) 49 (100%) 14 (88%) 0·06
Haemorrhage during admission
Yes 13 (20%) 7 (14%) 6 (37%) ··
No 52 (80%) 42 (86%) 10 (63%) 0·07
Blood product replacement
Platelets 21 (32%) 13 (27%) 9 (56%) 0·03
Fresh frozen plasma 15 (23%) 7 (14%) 9 (56%) 0·002
Red blood cells 8 (12%) 3 (6%) 5 (31%) 0·02
Ribavirin treatment
Yes 35 (54%) 23 (47%) 12 (75%) ··
No 30 (46%) 26 (53%) 4 (25%) 0·08
Data are n (%), mean (SD), or median (range; IQR). ROTEM=rotational thromboelastometry. 
Table 1: Demographics, clinical features, and treatment characteristics of patients with Crimean–Congo 
haemorrhagic fever by use of ROTEM analysis
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of 24 patients). At the time of bleeding, vital signs were 
within normal limits for 17 (68%) of 25 patients, with 
only one patient having a quick sepsis-related organ 
failure assessment (qSOFA) score of 2 or greater and a 
national early warning score (NEWS) greater than 3. 
Ribavirin treatment was given to 35 (54%) of 65 patients 
at a standard dose: 30 mg/kg loading dose, then 
15 mg/kg every 6 h for 4 days, and then 7·5 mg/kg every 
8 h for 6 days.18
Haematological variables on admission (n=45) are 
shown in table 2. Patients with moderate to severe 
disease had significantly lower platelet counts and more 
prolonged activated partial thromboplastin time than 
did those with mild disease. Haemoglobin, white blood 
All patients
(n=45)
Patients with mild 
disease (n=31)
Patients with moderate 
to severe disease (n=14)
p value
Haematology variables
Platelets, × 10⁹ cells per L (range; IQR) 73 (4–162; 55–113) 90 (46–166; 71–125) 46 (4–108; 29–66) <0·0001
White blood cells, × 10⁹ cells per L (range; IQR) 2·4  
(0·74–28·3; 1·53–3·35)
2·35 
(0·74–5·31; 1·48–3·11)
2·45 
(0·85–28·3; 1·52–3·70)
0·74
Prothrombin time, s* 14·0 (4·4) 13·1 (2·1) 15·8 (7·0) 0·08
Activated partial thromboplastin time, s* 38·3 (13·8) 32·8 (6·7) 49·9 (17·8) <0·0001
Haemoglobin, g/dL 13·5 (2·1) 13·8 (1·8) 12·7 (2·6) 0·10
ROTEM (EXTEM S) variables
Clotting time, s
Median (range; IQR) 59 (42–164; 49–69) 56 (42–81; 48–64) 69 (48–164; 54–75) 0·01
38–79 s 42 30 12 ··
>79 s 3 1 2 ··
Amplitude at 10 min, mm
Mean (SD) 41·6 (9·1) 45·1 (7·0) 33·9 (8·6) <0·0001
43–65 mm 19 17 2 ··
<43 mm 26 14 12 ··
Clot formation time, s
Median (range; IQR) 165 (72–418; 130–201) 147 (72–255; 109–171) 197 (98–418; 156–296) 0·006
34–159 s (normal range) 20 16 4 ··
160–220 s (usually unimpaired haemostasis with 
reduced n reserve)
17 13 4 ··
221–300 s (bleeding risk) 6 2 4 ··
301–400 s (high bleeding risk) 0 0 0 ··
>400 s (usually no effective haemostasis) 2 0 2 ··
Maximum clot firmness, mm
Mean (SD) 51·5 (10·1) 54·4 (7·2) 45·1 (12·5) 0·003
≥50 mm (normal range) 24 21 3 ··
46–49 mm (usually unimpaired haemostasis with 
reduced n reserve)
12 7 5 ··
40–45 mm (bleeding risk) 6 3 3 ··
30–39 mm (high bleeding risk) 2 0 2 ··
<30 mm (usually no effective haemostasis) 1 0 1 ··
Lysis index at 60 min >15% 0 0 0 NA
ROTEM (FIBTEM S) variables
Amplitude at 10 min, mm
Median (range; IQR) 13 (6–25; 10–15) 13 (8–20; 11–15) 12 (6–25; 10–15) 0·68
7–23 mm 42 29 13 ··
<7 mm 1 0 1 ··
Maximum clot firmness, mm
Median (range; IQR) 15 (7–60; 13–21) 15 (9–60; 13–21) 17 (7–39; 13–23) 0·21
9–25 mm 41 29 12 ··
<9 mm 2 0 2 ··
Data are n, mean (SD), or median (range; IQR). NA=not available. ROTEM=rotational thromboelastometry. EXTEM S=extrinsically activated ROTEM. FIBTEM S=fibrin-specific 
ROTEM. *28 patients in mild group and 13 in moderate to severe group.
Table 2: Haematology and ROTEM data at admission (<48 h) by severity of Crimean–Congo haemorrhagic fever
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cell count, and prothrombin time did not differ 
significantly at admission by disease severity. ROTEM 
analysis at admission (n=45) showed significant 
differences in all EXTEM S variables by disease severity, 
with clotting time, amplitude at 10 min after clotting 
time, clot formation time, and maximum clot firmness 
all having more abnormal values in the moderate to 
severe group than in the mild group (table 2; figure 2). 
There was no evidence of hyperfibrinolysis (>15%) at 1 h 
in any of the patients. Maximal clot firmness, clot 
formation time, PLTEM, and amplitude at 10 min after 
clotting time were significantly correlated with platelet 
count (p<0·0001; appendix). Prothrombin time 
correlated with clotting time (p<0·0001; appendix). For a 
disease thought to be associated with disseminated 
intravascular coagulation, amplitude at 10 min after 
clotting time and maximum clot firmness recorded by 
FIBTEM S did not differ significantly between the 
disease severity groups (table 2).
During hospital admission, among the patients with 
EXTEM S clot formation time measurements that showed 
increased bleeding risk (>221 s), 17 (71%) of 24 patients had 
platelet counts greater than 20 × 10⁹ cells per L and five 
(21%) of 24 had counts greater than 50 × 10⁹ cells per L. Of 
the patients with EXTEM S maximum clot firmness values 
showing bleeding risk (<46 mm), 18 (75%) of 24 patients 
had platelet counts greater than 20 × 10⁹ cells per L and five 
(21%) of 24 had platelet counts greater 50 × 10⁹ cells per L, 
again suggesting that the platelet count was not the 
determining factor of bleeding risk (appendix).
Clotting time did not differ significantly by day of 
illness (p=0·68; appendix). Results of the EXTEM S 
analysis of amplitude at 10 min after clotting time and 
maximum clot firmness differed by day of illness, with 
Figure 2: Haematological, coagulation, and rotational thromboelastometry (ROTEM) findings at admission in 45 patients with Crimean–Congo haemorrhagic fever disease, 
stratified by severity
Boxes represent median, 25th, and 75th centiles. Whiskers represent maximum and minimum values. Dotted lines represent limits of normal ranges. EXTEM S=extrinsically activated ROTEM. 
FIBTEM S=fibrin-specific ROTEM.
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lowest values occurring on day 4 (p=0·090) and day 6 of 
illness (p=0·024; appendix). The EXTEM S lysis index at 
60 min did not differ significantly by day of illness, with 
no abnormal results. FIBTEM S amplitude at 10 min 
after clotting time showed significant differences by day 
of illness in acute samples, with days 0–3 and 4–6 having 
the lowest values (p=0·003), but only one of 93 fibrinogen 
values was lower than normal (<7 s). FIBTEM S 
maximum clot firmness was also lowest on days 0–3 and 
4–6 (p=0·082 for the three timepoints evaluated together 
by linear regression models). All EXTEM S and FIBTEM 
S variables in convalescence (n=12) were within normal 
ranges. EXTEM S variables of clotting time (p=0·013), 
amplitude at 10 min after clotting time (p<0·001), clot 
formation time (p<0·001), and maximum clot firmness 
(p<0·001) were significantly worse in acute versus 
convalescent samples, but FIBTEM S did not differ 
significantly between acute and convalescent samples.
Details of a typical case of Crimean–Congo haemorrhagic 
fever, with ROTEM data, standard haematological 
and coagulation variables, and TEMograms, is shown in 
figure 3. Two patients died. The first was a man aged 
69 years who had no episodes of bleeding, normal ROTEM 
variables, and died from a hospital-acquired infection 
(Staphylococcus aureus septicaemia). The second was a 
woman aged 52 years who presented on day 4 of illness 
and then rapidly developed septic shock with minor 
bleeding from the oral mucosa, nose, and intravenous 
access sites. Bloods results at admission for the second 
patient were as follows: activated partial thromboplastin 
time 120 s, prothrombin time 40 s, and platelets 
28 × 10⁹ cells per L. ROTEM values at admission were 
highly abnormal: EXTEM S clotting time 164 s, amplitude 
at 10 min after clotting time 33 mm, clot formation time 
240 s, maximum clot firmness 46 mm, lysis index at 
60 min less than 15% (no evidence of hyperfibrinolysis), 
FIBTEM amplitude at 10 min after clotting time 7 mm, 
and maximum clot firmness 7 mm. The second patient 
developed multiorgan failure, dying within 36 h of 
admission, despite ribavirin treatment. The patient 
received two units of platelets and six units of fresh frozen 
plasma on each day of admission.
Figure 3: Illustrative case with serial ROTEM analyses
Case history: male patient aged 30 years, admitted 3 days after a tick bite with a 1-day history of fever, lethargy, headache, and anorexia. The patient developed gingival bleeding on days 7 and 8 of 
illness and was discharged on day 11 of illness. The patient did not receive any blood products during admission. (A) Haematological and coagulation variables. (B) ROTEM EXTEM S variables by day of 
illness. (C) EXTEM S TEMogram at day 6 of illness. (D) ROTEM EXTEM S TEMogram on day 10 of illness. EXTEM=extrinsically activated ROTEM. ROTEM=rotational thromboelastometry. 
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Discussion
Crimean–Congo haemorrhagic fever is a major emerging 
infectious disease threat and, although ribavirin is 
frequently used, the mainstay of case management is 
supportive care. Haemorrhage often occurs in severe 
disease and traditional laboratory tests (prothrombin 
time and activated partial thromboplastin time) do not 
show substantial abnormalities. This finding suggests 
that the coagulopathy seen in patients with Crimean–
Congo haemorrhagic fever is not due to disseminated 
intravascular coagulation but rather due to defects in 
platelet number or function, or fibrinolysis. This study is, 
to the best of our knowledge, the first to investigate the 
use of a global haemostasis test, ROTEM, alongside 
conventional testing in Crimean–Congo haemorrhagic 
fever.
Results of traditional coagulation tests were within the 
normal range of values and yet many patients had 
bleeding. On admission, most patients (42 [93%] of 45) 
had normal EXTEM S clotting times, showing that 
initiation of clotting, thrombin formation, and the start 
of clot polymerisation were not significantly abnormal in 
most patients at this point. By contrast, EXTEM S clot 
formation times were abnormal in most patients at 
admission. Clot formation time represents the time from 
initiation of clotting until a clot firmness of 20 mm is 
detected and elevated results indicate problems with 
fibrin polymerisation and stabilisation of the clot with 
factor XIII and platelets. In the face of normal or slightly 
deranged activated partial thromboplastin time and 
prothrombin time, this result points to a platelet or 
factor XIII defect.
In keeping with the results of clot formation time, 
maximum clot firmness was abnormal in about half of 
patients on admission and was highly deranged in a fifth. 
Abnormal values for maximum clot firmness indicate 
reduced stabilisation of the clot by the polymerised fibrin, 
platelets, and factor XIII. Significant activation of 
fibrinolysis can be discounted as no significant reduction 
was observed in maximum clot firmness or clot lysis in 
any patient. In FIBTEM S, coagulation is activated as 
in EXTEM S but the addition of cytochalasin D, an 
antiplatelet agent, blocks the effects of platelets. The 
resulting clot formation therefore depends only on fibrin 
formation and fibrin polymerisation, which mainly 
relates to fibrinogen concentrations. Our results show 
that, at admission, most patients had a normal FIBTEM S 
amplitude at 10 min after clotting time and maximum clot 
firmness, indicating normal fibrinogen concentrations. 
Disseminated intravascular coagulation is characterised 
by consumption of coagulation factors, with the formation 
of small thrombi throughout the vasculature leading 
to end organ failure. A key finding in disseminated 
intravascular coagulation is the presence of hypo- 
fibrinogenaemia and activation of fibrinolysis. The 
absence of significantly low fibrinogen concentrations 
and of activation of fibrinolysis are therefore out of 
keeping with a diagnosis of disseminated intravascular 
coagulation.
We detected a reversible coagulopathy in patients who 
survived Crimean–Congo haemorrhagic fever. Combined 
data from acute samples showed significant differences 
in all EXTEM S variables compared with those in 
convalescent samples taken after discharge in a subset of 
survivors, which showed ROTEM results within normal 
ranges. When acute samples were stratified by day of 
illness, days 4–6 had the most abnormal values, 
indicating that this is the major coagulopathic period in 
Crimean–Congo haemorrhagic fever with respect to a 
patient’s ability to generate stable clots. Although we 
observed no significant difference in median clotting 
time, the highest percentage of abnormal clotting time 
results was also found in days 4–6. This finding is 
consistent with previous reports and consensus that 
patients with severe Crimean–Congo haemorrhagic fever 
begin to haemorrhage during days 3–6.19
We plan to investigate factor XIII further but consider 
it unlikely to be the cause of the bleeding defect because 
of the clinical pattern of bleeding from mucous 
membranes, which is in keeping with a platelet defect. 
This defect was not simply due to thrombocytopenia, as 
patients with platelet counts higher than 50 × 10⁹ per L 
did not have spontaneous bleeding.
The two viral haemorrhagic fevers investigated for 
platelet dysfunction (Lassa fever and Argentinian 
haemorrhagic fever) have shown a clear platelet function 
defect on platelet aggregometry.8,20 It is logical to consider 
that all viral haemorrhagic fevers will have similar 
pathogenic pathways and produce similar patterns of 
bleeding. The platelet defect could be due to a change in 
von Willebrand factor, possibly through the loss of large 
molecular weight forms. However, this possibility is 
unlikely, as a change in von Willebrand factor is usually 
either due to high shear stresses or an antibody against 
von Willebrand factor, and has never been associated 
with a viral disease. We believe our findings exclude 
disseminated intravascular coagulation as the cause of 
the bleeding defect in patients presenting with Crimean–
Congo haemorrhagic fever. Disseminated intravascular 
coagulation is characterised by a consumptive coagu- 
lopathy associated with low platelet counts (which we 
found in our analysis), as well as low FIBTEM values, 
prolonged prothrombin time, and activated partial 
thromboplastin time, with prolongation of clotting time, 
all reflecting low coagulation factors21: these were not 
seen in this study. However, as shown by the second 
patient who died in our study, disseminated intravascular 
coagulation can occur in fatal cases of Crimean–Congo 
haemorrhagic fever associated with preterminal 
multiorgan failure.
A limitation of our study is that fewer patients with 
severe or fatal disease were recruited than expected, but 
we were able to show that the coagulopathy occurred in 
those with mild disease. The clinical and laboratory data 
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we report are consistent with those from larger cohorts 
in Turkey in which prothrombin time prolongation 
occurred in 14 (3%) of 404 patients and an activated 
partial thromboplastin time longer than 70 s was seen in 
15 (4%) of 404 patients.16 Crimean–Congo haemorrhagic 
fever severity scores were developed to predict mortality 
and have been validated in health-care settings in 
Turkey16,17 where there is access to good supportive care 
and blood transfusion. In this study, some patients had 
data missing at admission for severity score calculation, 
which potentially risked underscoring of some patients. 
However, data imputation with maximum and minimum 
scores did not change the severity grouping of most 
patients or alter the significance of the results (data not 
shown). Prognostic scoring at baseline is challenging 
and existing scoring systems require laboratory variables, 
which are not routinely available in all settings. In 
routine practice, simple variables such as a platelet count 
lower than 50 × 10⁹ cells per L are used as the trigger for 
referral to tertiary centres, indicating more severe 
disease, increased likelihood of haemorrhage, and the 
possible need for blood transfusion.3
Given the observational nature of the study we did not 
do multivariate analysis or analyse data stratified by 
subsequent ribavirin use. Likewise, we could not analyse 
data on blood component therapy use in relation 
to ROTEM variables. The decision to use blood 
components was up to the treating clinicians with non-
protocolised practice. ROTEM analysis was also not 
routinely done at specific timepoints after transfusion to 
allow evaluation of the effect of transfusion on 
haemostasis, which we plan to evaluate in future 
studies. We have shown that use of ROTEM in Crimean–
Congo haemorrhagic fever is feasible and can provide 
safe and rapid point-of-care results. A limitation of 
ROTEM is that it does not reflect what happens in blood 
vessels because of its inability to reproduce the 
endothelium. Although ROTEM is unable to confirm 
platelet dysfunction or factor XIII deficiency, potential 
defects can be inferred from ROTEM data and clinical 
patterns of bleeding. Serial daily ROTEM analysis of all 
cases would provide more complete data, but we were 
limited by the practical challenges of time required for 
analysis, high caseloads, and safety considerations. 
Earlier recruitment of patients during the course of the 
illness would have provided more data about the 
progression of the coagulopathy, but was limited by 
delays in presentation and the time required for 
recruiting patients and obtaining informed consent.
Management of Crimean–Congo haemorrhagic fever is 
challenging because few therapeutics are available and the 
infection is associated with high mortality. Our ROTEM 
and conventional coagulation analysis has shown that the 
coagulopathy of Crimean–Congo haemorrhagic fever is 
predominantly related to clot development and stabilisation 
that is most marked during days 4–6 of the illness and in 
severe disease. In the context of normal or only slightly 
deranged coagulation screens and FIBTEM results, and 
combined with the absence of hyper- fibrinolysis, this study 
provides the first evidence that the initial coagulopathy 
seen in Crimean–Congo haemorrhagic fever probably 
relates to platelet dysfunction. Further studies are required 
to confirm these findings and explore possible mechanisms 
for this platelet dysfunction.
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